(QTRX) Quanterix - Ratings and Ratios
Instruments, Assays, Reagents, Services
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 73.6% |
| Value at Risk 5%th | 106% |
| Relative Tail Risk | -12.67% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.06 |
| Alpha | -44.81 |
| CAGR/Max DD | -0.25 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.522 |
| Beta | 1.690 |
| Beta Downside | 1.654 |
| Drawdowns 3y | |
|---|---|
| Max DD | 85.07% |
| Mean DD | 44.66% |
| Median DD | 51.19% |
Description: QTRX Quanterix December 31, 2025
Quanterix Corporation (NASDAQ:QTRX) is a life-sciences firm that develops and markets digital immunoassay platforms designed to enable ultra-sensitive protein detection for precision health research and diagnostics across North America, Europe, the Middle East, Africa, and the Asia-Pacific.
The company’s flagship instruments include the HD-X (single-plex protein detection), the SR-X (expanded Simoa applications), and the SP-X (planar-array multiplex chemiluminescent immunoassays). Complementary consumables-beads, capture/detector reagents, enzymes, substrates, and replacement parts-are sold alongside custom assay-development and contract-research services such as home-brew assay creation, LDT testing, and Lucent Diagnostic services.
Quanterix primarily serves the neurology, oncology, immunology, and inflammation markets, supplying academic, government, pharmaceutical, biotech, and CRO laboratories through a mix of direct field sales, support organizations, and distributor networks.
Recent performance indicators show QTRX’s Q3-2024 revenue grew ~22% YoY to $45 million, driven by a 35% increase in Simoa-based assay orders and expanding adoption in early-stage oncology biomarker programs. The broader life-sciences tools sector is benefiting from a 12% annual rise in global R&D spend and a secular shift toward ultra-sensitive diagnostics, which underpins Quanterix’s addressable market.
For a deeper dive into how Quanterix’s metrics compare to peers, you might explore ValueRay’s analyst toolkit for additional context.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -95.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA -5.14 > 1.0 |
| NWC/Revenue: 120.9% < 20% (prev 249.4%; Δ -128.5% < -1%) |
| CFO/TA -0.15 > 3% & CFO -65.1m > Net Income -95.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.1m) vs 12m ago 19.80% < -2% |
| Gross Margin: 51.07% > 18% (prev 0.58%; Δ 5049 % > 0.5%) |
| Asset Turnover: 30.17% > 50% (prev 32.24%; Δ -2.08% > 0%) |
| Interest Coverage Ratio: -19.64 > 6 (EBITDA TTM -93.3m / Interest Expense TTM -5.43m) |
Altman Z'' (< 1.1 .. > 2.6) -7.93
| A: 0.35 (Total Current Assets 233.3m - Total Current Liabilities 77.4m) / Total Assets 444.1m |
| B: -1.25 (Retained Earnings -554.1m / Total Assets 444.1m) |
| C: -0.25 (EBIT TTM -106.6m / Avg Total Assets 427.6m) |
| D: -4.28 (Book Value of Equity -554.9m / Total Liabilities 129.6m) |
| Altman-Z'' Score: -7.93= D |
ValueRay F-Score (Strict, 0-100) 26.16
| 1. Piotroski: 1.50pt |
| 2. FCF Yield: -27.18% |
| 3. FCF Margin: -52.89% |
| 4. Debt/Equity: 0.13 |
| 5. Debt/Ebitda: data missing |
| 6. ROIC - WACC: -40.28% |
| 7. RoE: -30.53% |
| 8. Revenue Trend: 49.65% |
| 9. EPS Trend: 18.87% |
What is the price of QTRX shares?
Over the past week, the price has changed by -4.08%, over one month by +3.68%, over three months by +16.34% and over the past year by -27.47%.
Is QTRX a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the QTRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.3 | 4% |
| Analysts Target Price | 7.3 | 4% |
| ValueRay Target Price | 6.6 | -7.1% |
QTRX Fundamental Data Overview January 18, 2026
P/B = 1.1806
Revenue TTM = 129.0m USD
EBIT TTM = -106.6m USD
EBITDA TTM = -93.3m USD
Long Term Debt = 40.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 8.41m USD (from shortTermDebt, last quarter)
Debt = 40.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.82m USD (from netDebt column, last quarter)
Enterprise Value = 251.0m USD (345.7m + Debt 40.1m - CCE 134.8m)
Interest Coverage Ratio = -19.64 (Ebit TTM -106.6m / Interest Expense TTM -5.43m)
EV/FCF = -3.68x (Enterprise Value 251.0m / FCF TTM -68.2m)
FCF Yield = -27.18% (FCF TTM -68.2m / Enterprise Value 251.0m)
FCF Margin = -52.89% (FCF TTM -68.2m / Revenue TTM 129.0m)
Net Margin = -74.17% (Net Income TTM -95.7m / Revenue TTM 129.0m)
Gross Margin = 51.07% ((Revenue TTM 129.0m - Cost of Revenue TTM 63.1m) / Revenue TTM)
Gross Margin QoQ = 42.65% (prev 46.12%)
Tobins Q-Ratio = 0.57 (Enterprise Value 251.0m / Total Assets 444.1m)
Interest Expense / Debt = 30.88% (Interest Expense 12.4m / Debt 40.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -84.2m (EBIT -106.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.02 (Total Current Assets 233.3m / Total Current Liabilities 77.4m)
Debt / Equity = 0.13 (Debt 40.1m / totalStockholderEquity, last quarter 314.5m)
Debt / EBITDA = -0.02 (negative EBITDA) (Net Debt 1.82m / EBITDA -93.3m)
Debt / FCF = -0.03 (negative FCF - burning cash) (Net Debt 1.82m / FCF TTM -68.2m)
Total Stockholder Equity = 313.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -22.37% (Net Income -95.7m / Total Assets 444.1m)
RoE = -30.53% (Net Income TTM -95.7m / Total Stockholder Equity 313.4m)
RoCE = -30.15% (EBIT -106.6m / Capital Employed (Equity 313.4m + L.T.Debt 40.1m))
RoIC = -26.87% (negative operating profit) (NOPAT -84.2m / Invested Capital 313.4m)
WACC = 13.41% (E(345.7m)/V(385.8m) * Re(12.14%) + D(40.1m)/V(385.8m) * Rd(30.88%) * (1-Tc(0.21)))
Discount Rate = 12.14% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 1.34%
Fair Price DCF = unknown (Cash Flow -68.2m)
EPS Correlation: 18.87 | EPS CAGR: 20.25% | SUE: 2.94 | # QB: 1
Revenue Correlation: 49.65 | Revenue CAGR: 7.81% | SUE: 0.90 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.43 | Chg30d=+0.013 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=-1.41 | Chg30d=+0.120 | Revisions Net=-1 | Growth EPS=+37.0% | Growth Revenue=+27.0%
Additional Sources for QTRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle